5 Surprising Signs of Aging
Jancee Dunn / nytimes - Hint: You may need to buy new shoes.
AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.
Supercentenarians have an abundance of cancer-killing immune cells
medicalxpress - The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. When a person gets sick, these cells multiply in a process called clonal expansion to help fight infect…
AI Summary: Analyses of people over 110 reveal an abundance of highly active cytotoxic immune cells capable of recognizing and eliminating cancerous cells, offering clues to extreme longevity. These hypervigilant immune profiles may explain low cancer rates among the very old and suggest immune‑based strategies that could one day mimic their natural defenses.
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …
AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.
Essentia Health names EVP from SSM Health
Kelly Gooch / beckershospitalreview - Jason Craig, most recently a regional vice president at St. Louis-based SSM Health, was named executive vice president of administration and operations at Duluth, Minn.-based Essentia Health, according to an Aug. 12 news release shared with Becker’s. Mr. …
AI Summary: Recent analyses and expert commentary propose that genomic newborn screening can identify children with cancer predisposition syndromes before tumors develop. Early detection would enable targeted surveillance and preventive measures, though ethical, logistical, and equity considerations remain central to implementing such programs at scale. Expect lively debate before universal adoption.
International project delivers hundreds of next-generation models for cancer research
medicalxpress - Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available to scienti…
AI Summary: An international consortium released hundreds of patient‑derived tumor models, including a public HCMI set of 665 organoids, creating a living biobank for drug discovery. Labs worldwide now gain access to diverse, next‑generation models to test therapies and probe cancer vulnerabilities — a major boost for preclinical translational work.
- Experts react: three Nature papers and model summaries (3)
- HCMI release: 665 organoids unveiled in Nature (4)
- Organoids power maps and predictors of therapy resistance (4)
Experts react: three Nature papers and model summaries
HCMI release: 665 organoids unveiled in Nature
Organoids power maps and predictors of therapy resistance
Ancient Smallpox DNA Hidden in Two Chilean Mummies Traces the Disease’s Colonial Arrival
discovermagazine - Learn how centuries-old DNA linked an extinct virus to European colonization and its spread through an Indigenous community in northern Chile.
AI Summary: Researchers detected ancient smallpox DNA in two Chilean mummies, providing genomic evidence that European colonists introduced the virus to the Americas. The findings link historical outbreaks to colonial contact, illuminate pathogen spread centuries ago, and offer a tangible genetic record of the devastating diseases that reshaped indigenous populations.
Ghost DNA in Living Humans Reveals Two Unknown Ancient Human Lineages
discovermagazine - Learn how researchers uncovered two ancient human lineages without sequenced ancient DNA from either population.
AI Summary: Genomic analyses detected contributions from two previously unidentified "ghost" lineages in modern human DNA, indicating that ancient populations interbred more widely than the fossil record alone had suggested. The findings reshape models of prehistoric population structure, revealing hidden ancestry signals from extinct groups that persist in living people.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
livescience - A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
AI Summary: An investigation found a six‑year‑old patient died following an experimental gene‑editing treatment in China, and that the fatality was not promptly disclosed. The case has reignited scrutiny of the country’s gene therapy oversight and raised urgent questions about trial transparency, consent and regulatory enforcement.
Two Children With a Rare Epilepsy Mutation Show Improvement After Personalized Genetic Treatment
discovermagazine - Learn how personalized genetic therapy helped researchers treat two children with a rare form of epilepsy, enabling one to walk independently for the first time.
AI Summary: Two children with a rare, treatment‑resistant epilepsy mutation showed marked clinical improvement after receiving individualized genetic therapies—one via an antisense oligonucleotide tailored to the mutation. The cases underscore the promise of bespoke molecular medicines for devastating pediatric neurological disorders and hint that precision medicine can be both life‑changing and, yes, kind of miraculous.
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
fiercehealthcare - Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.
AI Summary: Tempus is acquiring cancer-genomics company Personalis for roughly $1.5 billion to expand its testing and genomic-service footprint, betting bigger on integrated sequencing and AI-driven oncology diagnostics. The move accelerates Tempus’s push to scale tumor profiling and clinical assays nationwide — and yes, expect louder claims about “transforming cancer care.”
How we are engineering bacteria to eat cancer
medicalxpress - Modern medicine has made significant advances in cancer treatments over the decades. But all cancer therapies still face one critical challenge: how to target cancers without damaging healthy cells.
AI Summary: Researchers engineered bacteria that selectively attack and consume tumor tissue in preclinical models, demonstrating promising tumor control and a novel mechanism to deliver anti‑cancer effects. Significant questions remain about safety, immune responses and delivery in humans, so while the “bacteria that eat cancer” headline is delightful, translation to patients will require cautious, rigorous steps.
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Genetic study redefines a form of excessive sweating as a treatable neurological condition
medicalxpress - An international research team led by Dr. Frank Bosmans (Vrije Universiteit Brussel) has discovered a major genetic cause of hyperhidrosis (chronic and excessive sweating). The study, published in Science Advances, provides strong evidence that a genetica…
AI Summary: New research identifies a genetic basis and a tiny electrically gated ion channel in nerve cells as drivers of a form of excessive sweating, recasting it as a neurological condition rather than a benign nuisance. Findings point to potential targeted therapies that address the underlying neural mechanism rather than symptom management alone.
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
Medieval babies and adults buried together in Sweden were not related, archaeologists discover — raising big questions about early Christian burial practices
livescience - In an unexpected discovery, researchers found that three medieval Swedish cemeteries held children buried with unrelated adults.
AI Summary: Archaeological and genetic analyses reveal medieval Swedish burial patterns that placed infants and children alongside unrelated adults, including female infants buried among men. The findings challenge assumptions about kinship‑based internment and suggest shifting funerary practices during early Christianization, prompting fresh questions about social identity and ritual in the period.
Parham Habibzadeh: ctDNA MRD After CRLM Resection Identifies Who Benefits From ACT!
oncodaily - Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT! Upfront surgery: MRD+ patients improved with […]
AI Summary: A growing body of evidence shows circulating tumor DNA (ctDNA) measured after colorectal liver metastasis resection can identify which patients truly benefit from adjuvant chemotherapy and who likely do not. This blood test promises more personalized postoperative care, reducing unnecessary toxicity and costs by targeting chemo to molecular minimal residual disease rather than gut instinct.
For the First Time, a Cell Built From Scratch Grows and Divides
Yasemin Saplakoglu / quantamagazine - Scientists built a synthetic cell that combines more lifelike properties than ever before — proof of concept that it’s possible to bring nonliving materials to life, or something close to it, in the lab. The post For the First Time, a Cell Built From Scra…
AI Summary: Scientists have for the first time built a synthetic cell from scratch that completes a full life cycle — growing and dividing in the lab. The milestone demonstrates control over core cellular processes, opening doors for bespoke biomanufacturing and disease modelling, while reviving familiar ethical and biosafety questions. Yes, it’s breathtaking — and yes, we should probably be cautious.
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, / science - Science Translational Medicine, Volume 18, Issue 856, July 2026.
AI Summary: Preclinical studies show CAR‑T cells engineered to target mutant calreticulin selectively eliminate disease‑driving clones in xenografts and human organoid models of myelofibrosis. The results reveal a potentially curative approach for a previously intractable mutation‑driven disease, though safety, on‑target effects and clinical translation remain to be rigorously tested.
First use of precision editing to study human embryo development reveals role of master gene
medicalxpress - Research led by the University of Cambridge Loke Center for Trophoblast Research has shown that a genome-editing technique can be used to alter a single gene in human embryonic cells, enabling the study of very early human development in unparalleled deta…
AI Summary: Scientists used precision genome editing in human embryos to identify a 'master' developmental gene that triggers early human development stages. The finding clarifies key molecular steps, offering insights into congenital disorders and embryology, but also reignites ethical debate over experimental editing — cue the lab‑coat philosophers.